Vitamin D ~ what more can I say?

[Guest guest]

CCAAT ENHANCER BINDING PROTEIN ÁLPHA IS A MOLECULAR TARGET OF

1,25DIHYDROXYVITAMIN D3 IN MCF 7 BREAST CANCER CELLS

http://www.jbc.org/cgi/doi/10.1074/jbc.M803602200

JBC Papers in Press. Published on December 3, 2008 as

Manuscript M803602200

[[....INTRODUCTION

Vitamin D, in order to exert its effects, must be metabolized to its

most active form, 1,25dihydroxyvitaminD3 (1,25(OH)2D3) (1).

The actions of 1,25(OH)2D3 include not only maintenance of calcium

homeostasis but also effects on numerous other systems including

effects on the immune system and the growth and differentiation of a

number of malignant cells including breast cancer cells (1).

1,25(OH)2D3 acts by binding to a high affinity intracellular receptor

protein (the vitamin D receptor or VDR). 1,25(OH)2D3 bound to the VDR

heterodimerizes with the retinoid X receptor (RXR) and along with

coactivators and additional accessory nuclear proteins interacts with

vitamin D response elements (VDREs) in the promoter of target genes

and modulates their transcription (1). .....]]